Evidence map›Paper›PMID 26630613›Full record

ArticleJournal of affective disorders2016

Structural connectivity and response to ketamine therapy in major depression: A preliminary study.

Megha M Vasavada, Amber M Leaver, Randall T Espinoza, Shantanu H Joshi, Stephanie N Njau, Roger P Woods, Katherine L Narr

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of affective disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04234776 (Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression), which is not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04234776 phase4unknown statusnot on this mapstarted 2018, after this paper: background citation

Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression

TypeinterventionalSponsorUniversity of Sao PauloRan2018 to 2021Enrolled88ConditionsDepressive DisorderArmsKetamine, Cognition, Suicide risk, Depression thoughts, Quality of life and disability
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. White matter predicts tDCS antidepressant effects in a sham-controlled clinical trial study.European archives of psychiatry and clinical neuroscience · 2023
    Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. A review of diffusion MRI in mood disorders: mechanisms and predictors of treatment response.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Review
  14. Article
  15. Article
  16. Article
  17. Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2023
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Megha M VasavadaAhmanson-Lovelace Brain Mapping Center, Department of Neurology, Geffen School of Medicine at the University of California, Los Angeles, CA, USA.
Amber M LeaverAhmanson-Lovelace Brain Mapping Center, Department of Neurology, Geffen School of Medicine at the University of California, Los Angeles, CA, USA.
Randall T EspinozaJane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine at the University of California, Los Angeles, CA, USA.
Shantanu H JoshiAhmanson-Lovelace Brain Mapping Center, Department of Neurology, Geffen School of Medicine at the University of California, Los Angeles, CA, USA.
Stephanie N NjauAhmanson-Lovelace Brain Mapping Center, Department of Neurology, Geffen School of Medicine at the University of California, Los Angeles, CA, USA.
Roger P WoodsAhmanson-Lovelace Brain Mapping Center, Department of Neurology, Geffen School of Medicine at the University of California, Los Angeles, CA, USA; Jane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine at the University of California, Los Angeles, CA, USA.
Katherine L NarrAhmanson-Lovelace Brain Mapping Center, Department of Neurology, Geffen School of Medicine at the University of California, Los Angeles, CA, USA; Jane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine at the University of California, Los Angeles, CA, USA. Electronic address: narr@ucla.edu.

Funding

Imaging biomarkers of ECT response in major depressive disorderR01MH092301 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ESPINOZA, RANDALL, NARR, KATHERINE L · 2011 to 2015
$4.0M
Biomarkers of fast acting therapies in major depressionK24MH102743 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NARR, KATHERINE L · 2014 to 2018
$889k
NIMH NIH HHS K24 MH102743NIMH NIH HHS K24MH102743NIMH NIH HHS R01 MH092301NIMH NIH HHS R01MH092301
6 · The paper itself

Abstract

backgroundKetamine elicits an acute antidepressant effect in patients with major depressive disorder (MDD). Here, we used diffusion imaging to explore whether regional differences in white matter microstructure prior to treatment may predict clinical response 24h following ketamine infusion in 10 MDD patients.

methodsFSL's Tract-Based Spatial Statistics (TBSS) established voxel-level differences in fractional anisotropy (FA) between responders (patients showing >50% improvement in symptoms 24h post-infusion) and non-responders in major white matter pathways. Follow-up regions-of-interest (ROI) analyses examined differences in FA and radial (RD), axial (AD) and mean diffusivity (MD) between responders and non-responders and 15 age- and sex-matched controls, with groups compared pairwise.

resultsWhole brain TBSS (p<0.05, corrected) and confirmatory tract-based regions-of-interest analyses showed larger FA values in the cingulum and forceps minor in responders compared to non-responders; complementary decreases in RD occurred in the cingulum (p<0.05). Only non-responders differed from controls showing decreased FA in the forceps minor, increased RD in the cingulum and forceps minor, and increased MD in the forceps minor (p<0.05). LIMITATIONS: Non-responders showed an earlier age of onset and longer current depressive episode than responders. Though these factors did not interact with diffusion metrics, results may be impacted by the limited sample size.

conclusionsThough findings are considered preliminary, significant differences in FA, RD and MD shown in non-responders compared to responders and controls in fronto-limbic and ventral striatal pathways suggest that the structural architecture of specific functional networks mediating emotion may predict ketamine response in MDD.

Indexed as

AdultAnisotropyAntidepressive AgentsCase-Control StudiesCorpus CallosumDiffusion Tensor ImagingFemaleFollow-Up StudiesFrontal LobeHumansKetamineMajor Depressive DisorderMaleMiddle AgedNerve FibersTreatment OutcomeAntidepressive AgentsKetamineBiomarkersDiffusion Tensor Imaging (DTI)Fractional anisotropy (FA)GlutamateTreatment response

Identifiers

PMID26630613
PMCPMC4685004

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.